ELV (Elevance Health, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ELV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Erin M Wessling | EVP & Chief Legal Officer | F | — | — |
| 2026-09-04 | Ryan R Craig | EVP & Chief HR Officer | F | — | — |
| 2026-07-17 | GAIL BOUDREAUX | President and CEO | Buy | — | — |
| 2026-07-17 | RAMIRO G PERU | Director | Buy | — | — |
| 2026-06-15 | Ronald W Penczek | CAO & Controller | Sell | — | — |
| 2026-06-12 | Robert L Dixon JR | Director | Sell | — | — |
| 2026-05-20 | Ronald W Penczek | CAO & Controller | MIXED | — | — |
| 2026-05-15 | STEVEN H COLLIS | Director | A | — | — |
| 2026-05-15 | Susan D. DeVore | Director | A | — | — |
| 2026-05-15 | Robert L Dixon JR | Director | A | — | — |
| 2026-05-15 | LEWIS HAY III | Director | A | — | — |
| 2026-05-15 | Bahija Jallal | Director | A | — | — |
| 2026-05-15 | Antonio F Neri | Director | A | — | — |
| 2026-05-15 | RAMIRO G PERU | Director | A | — | — |
| 2026-05-15 | Ryan M. Schneider | Director | A | — | — |
| 2026-05-15 | AMY W SCHULMAN | Director | A | — | — |
| 2026-05-15 | DEANNA D STRABLE-SOETHOUT | Director | A | — | — |
| 2026-03-23 | AMY W SCHULMAN | Director | Sell | — | — |
| 2026-03-09 | Charles Morgan Kendrick JR | EVP & President, Commercial | Sell | — | — |
| 2026-03-06 | STEVEN H COLLIS | Director | Buy | — | — |
| 2026-03-04 | GAIL BOUDREAUX | President and CEO | MIXED | — | — |
| 2026-03-04 | Mark Kaye | EVP & CFO | MIXED | — | — |
| 2026-03-04 | Peter D Haytaian | EVP & Pres Carelon & CarelonRx | MIXED | — | — |
| 2026-03-04 | Charles Morgan Kendrick JR | EVP & President, Commercial | MIXED | — | — |
| 2026-03-04 | RATNAKAR LAVU | EVP & Chief Digital Info Ofr | MIXED | — | — |
| 2026-03-04 | Felicia F Norwood | EVP &Chief Health Benefits Ofr | MIXED | — | — |
| 2026-03-04 | Ryan R Craig | EVP & Chief HR Officer | MIXED | — | — |
| 2026-03-04 | Erin M Wessling | EVP & Chief Legal Officer | MIXED | — | — |
| 2026-03-04 | Ronald W Penczek | CAO & Controller | MIXED | — | — |
| 2026-02-03 | Ryan R Craig | EVP & Chief HR Officer | F | — | — |
| 2026-02-03 | AMY W SCHULMAN | Director | A | — | — |
| 2025-10-03 | Mark Kaye | EVP & CFO | F | — | — |
| 2025-09-05 | Erin M Wessling | EVP & Chief Legal Officer | F | — | — |
| 2025-09-04 | Ryan R Craig | EVP & Chief HR Officer | A | — | — |
| 2025-09-04 | Erin M Wessling | EVP & Chief Legal Officer | A | — | — |
| 2025-08-21 | Susan D. DeVore | Director | Buy | — | — |
| 2025-08-05 | STEVEN H COLLIS | Director | A | — | — |
| 2025-07-18 | GAIL BOUDREAUX | President and CEO | Buy | — | — |
| 2025-05-16 | R KERRY CLARK | Director | A | — | — |
| 2025-05-16 | Susan D. DeVore | Director | A | — | — |
| 2025-05-16 | Robert L Dixon JR | Director | A | — | — |
| 2025-05-16 | LEWIS HAY III | Director | A | — | — |
| 2025-05-16 | Bahija Jallal | Director | A | — | — |
| 2025-05-16 | Antonio F Neri | Director | A | — | — |
| 2025-05-16 | RAMIRO G PERU | Director | A | — | — |
| 2025-05-16 | Ryan M. Schneider | Director | A | — | — |
| 2025-05-16 | DEANNA D STRABLE-SOETHOUT | Director | A | — | — |
| 2025-04-25 | Mark Kaye | EVP & CFO | Sell | — | — |
| 2025-03-11 | Ronald W Penczek | CAO & Controller | Sell | — | — |
| 2025-03-05 | GAIL BOUDREAUX | President and CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 169,991 | — |
| — | EVP & Chief Financial Officer | 63,725 | — |
| — | EVP & Chief Administrative Off | 51,435 | — |
| — | EVP &Chief Health Benefits Ofr | 36,469 | — |
| — | EVP & CFO | 32,390 | — |
| — | EVP & Pres Carelon & CarelonRx | 24,803 | — |
| — | EVP, CLO & CAO | 15,631 | — |
| — | Director | 12,070 | — |
| — | EVP & President, Commercial | 11,791 | — |
| — | Director | 10,908 | — |
| — | Director | 10,734 | — |
| — | Director | 10,291 | — |
| — | Director | 9,640 | — |
| — | EVP & Chief Legal Officer | 7,230 | — |
| — | Director | 7,163 | — |
| — | EVP & Chief HR Officer | 6,530 | — |
| — | Director | 5,488 | — |
| — | Director | 5,351 | — |
| — | EVP & Chief Digital Info Ofr | 4,468 | — |
| — | Director | 4,202 | — |
| — | Director | 4,065 | — |
| — | CAO & Controller | 3,740 | — |
| — | Director | 2,209 | — |
| — | Director | 781 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ELV quote page; the site-wide leaderboard is on the insider transactions hub.